Stempeutics receives Japan process patent for its novel stem cell drug ‘Stempeucel’

Cipla Ltd. | Pharmaceuticals & Drugs | Healthcare | BSE: 500087 | NSE: CIPLA

08 Jun 2015 Evaluate

Stempeutics Research, a group company of Manipal Education and Medical Group and a Joint Venture with Cipla Group, has been granted process patent from the Japan Patent Office (application no 2012-540529) for its novel stem-cell based drug Stempeucel. The novelty covers the method of preparing master cell banks, working cell banks and the final therapeutic product ‘Stempeucel’ based on the novel pooling technology. Stempeucel will initially be used for the treatment of CLI, a breakthrough treatment option which directly addresses the root cause of the disease, unlike other drugs which typically treat the symptoms and not the disease itself.

Stempeucel is derived from allogeneic pooled mesenchymal stromal cells extracted from the bone marrow of healthy, adult voluntary donors. The company proprietary pooling approach allows an efficient manufacturing process with minimum wastage of resources in order to provide the product at an affordable cost to patients. This approach also allows more than one million patient doses from a single set of master cell banks, which is unique in regenerative medicine. The proprietary technology allows Stempeucel to extend the therapeutic potential of the drug across multiple disease categories.

Cipla has emerged as one of the most respected pharmaceutical names in India as well as across more than 170 countries. Its portfolio includes over 2000 products in 65 therapeutic categories with one quality standard globally.